Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 7-hydroxy-3-hydroxyphenyl-1h-benzopyran
2. Phenoxodiol
1. Phenoxodiol
2. Dehydroequol
3. 81267-65-4
4. Haginin E
5. 3-(4-hydroxyphenyl)-2h-chromen-7-ol
6. 3-(4-hydroxyphenyl)-2h-1-benzopyran-7-ol
7. Nv-06
8. 7,4'-dihydroxyisoflav-3-ene
9. 2h-1-benzopyran-7-ol, 3-(4-hydroxyphenyl)-
10. Idronoxil;dehydroequol;haginin E
11. 995ft1w541
12. Nv 06
13. Idronoxil [usan]
14. Ccris 8949
15. Idronoxil (usan/inn)
16. Idronoxil [usan:inn]
17. 7-hydroxy-3-hydroxyphenyl-1h-benzopyran
18. Haganin E
19. Unii-995ft1w541
20. Idronoxil [inn]
21. Phenoxodiol (haginin E)
22. Dehydroequol [mi]
23. Isoflav-3-ene4',7-diol
24. Idronoxil [who-dd]
25. Isoflav-3-ene-4',7-diol
26. Mls006010720
27. Schembl149612
28. 4',7-dihydroxyisoflav-3-ene
29. Chembl1957038
30. Phenoxodiol, >=98% (hplc)
31. Dtxsid50231029
32. ...7,4?-dihydroxyisoflav-3-ene
33. Nox-66 Component Idronoxil
34. Zinc1491943
35. Bdbm50419932
36. S9634
37. Akos015918005
38. Db04915
39. 3-(4-hydroxy-phenyl)-2h-chromen-7-ol
40. Ncgc00346822-01
41. Ncgc00346822-02
42. Hy-13721
43. Smr004701684
44. Xd161580
45. Xd161694
46. Db-012327
47. Cs-0007751
48. Ft-0602222
49. Nox66 Suppository Component Idronoxil
50. D04498
51. Idronoxil Component Of Nox66 Suppository
52. 267p654
53. A853212
54. Q27095562
55. (+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2h-cromen-7-ol
| Molecular Weight | 240.25 g/mol |
|---|---|
| Molecular Formula | C15H12O3 |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 240.078644241 g/mol |
| Monoisotopic Mass | 240.078644241 g/mol |
| Topological Polar Surface Area | 49.7 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 318 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Intended for the treatment of various forms of cancer.
Phenoxodiol inhibits proliferation of many cancer cell lines and induces apoptosis by disrupting FLICE-inhibitory protein, FLIP, expression and by caspase-dependent and -independent degradation of the X-linked inhibitor of apoptosis, XIAP. In addition, phenoxodiol sensitizes drug-resistant tumour cells to anticancer drugs including paclitaxel, carboplatin and gemcitabine.
The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Results from one study (PMID: 17904534) indicate that plasma membrane electron transport (PMET) may be a primary target for phenoxodiol in tumour cells and in activated T cells.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
98
PharmaCompass offers a list of Idronoxil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Idronoxil manufacturer or Idronoxil supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Idronoxil manufacturer or Idronoxil supplier.
PharmaCompass also assists you with knowing the Idronoxil API Price utilized in the formulation of products. Idronoxil API Price is not always fixed or binding as the Idronoxil Price is obtained through a variety of data sources. The Idronoxil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Idronoxil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Idronoxil, including repackagers and relabelers. The FDA regulates Idronoxil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Idronoxil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Idronoxil supplier is an individual or a company that provides Idronoxil active pharmaceutical ingredient (API) or Idronoxil finished formulations upon request. The Idronoxil suppliers may include Idronoxil API manufacturers, exporters, distributors and traders.
Idronoxil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Idronoxil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Idronoxil GMP manufacturer or Idronoxil GMP API supplier for your needs.
A Idronoxil CoA (Certificate of Analysis) is a formal document that attests to Idronoxil's compliance with Idronoxil specifications and serves as a tool for batch-level quality control.
Idronoxil CoA mostly includes findings from lab analyses of a specific batch. For each Idronoxil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Idronoxil may be tested according to a variety of international standards, such as European Pharmacopoeia (Idronoxil EP), Idronoxil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Idronoxil USP).
